Fate Therapeutics Coverage Initiated by Analysts at BMO Capital Markets (FATE)
Research analysts at BMO Capital Markets initiated coverage on shares of Fate Therapeutics (NASDAQ:FATE) in a report released on Monday, TheFlyOnTheWall.com reports. The firm set an “outperform” rating and a $14.00 price target on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 117.05% from the company’s current price.
Fate Therapeutics (NASDAQ:FATE) traded down 6.11% on Monday, hitting $6.45. 248,916 shares of the company’s stock traded hands. The stock’s 50-day moving average is $0. and its 200-day moving average is $0.. The company’s market cap is $123.6 million.
Fate Therapeutics, Inc, is a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat orphan diseases, including hematologic malignancies, lysosomal storage disorders and muscular dystrophies.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.